The Latest Cardiac and Vascular News
NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 24, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the […]
NASDAQ: CORV TSX: CORV Post Hoc Analysis of Subset of Patients Treated in the Emergency Department Setting Safety Outcomes of Interest Observed in Less Than 1% Cases; No Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus […]
VANCOUVER, July 25, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for […]
VANCOUVER, Feb. 7, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlighting the low rate of hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its […]
VANCOUVER, Oct. 29, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that it has received independent regulatory and legal opinions that Brinavess® (vernakalant hydrochloride, IV) may qualify […]
VANCOUVER, Oct. 23, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that, based on productive pre-NDA discussions with the U.S. Food […]
VANCOUVER, Aug. 16, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported positive data highlighting reduced hospitalization in patients […]
VANCOUVER, June 11, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that it has received a response from […]
VANCOUVER, June 6, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the Brinavess®study, titled “Vernakalant in hospital emergency practice: safety and effectiveness,” published by José Carbajosa Dalmau (Alicante, Spain), […]
